An interventional study of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in Aortic Valve Stenosis and Bicuspid Aortic Valve, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Aortic Valve Stenosis with a site in United States — 43 open to participants now, 67 under way, 3 of them phase 3. Aortic Valve Stenosis · United States.
Among the 189 studies in Aortic Valve Stenosis with a site in United States, this one is the 53rd largest by planned enrollment of the 125 interventional ones that give a count, is one of 12 that started in 2025, is one of 102 with no phase, reaches primary completion later than 43 of the 66 other live ones, and was the 173rd registered.
1,027 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →43 of the 189 studies in Aortic Valve Stenosis with a site in United States are open now. Recruiting first, the newest first:
American College of Cardiology · Sites in United States
Ages 18+
EmStop Inc · Sites in United States
Ages 22+
Dermed Diagnostics, Inc. · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 18+
MiRus · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 7 · Phase 4 6
First in 2000; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 172 across the 125 interventional studies, 102 across the 64 observational. Of the 107 that completed or were terminated, 50 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 189 have an industry lead sponsor. The 10 most frequent:
Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.
Cedars-Sinai Medical Center has 2 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
13 of the studies in Aortic Valve Stenosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06689839EnCompass Technologies, Inc.Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR | 2026-12 |
| NCT05603026University Hospitals Cleveland Medical CenterMRI in Transcatheter Aortic Valve Replacement Patients | 2026-12-30 |
| NCT07827105AccurKardia, Inc.ECG-based AI Screening for Cases of Undiagnosed Moderate-to-Severe Aortic Stenosis in the Primary Care Setting | 2027-02 |
| NCT06077201Vanderbilt University Medical CenterHome-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions | 2027-02-01 |
| NCT06580158Mayo ClinicAI in Outpatient Practice for Diagnosing Aortic Stenosis and Diastolic Dysfunction | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 189 studies in Aortic Valve Stenosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study protocol is a randomized trial of standard of care therapies for severe aortic stenosis (AS) in patients with a bicuspid aortic valve (BAV). Namely, the therapies to which patients will be randomized will be transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), in patients deemed clinically suitable for both following heart team review.
The purpose of this study is to compare the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) versus Surgical Aortic Valve Replacement (SAVR) for treating patients with severe aortic stenosis (AS) who have a congenital bicuspid aortic valve (BAV) anatomy. Patients with BAV anatomy have been under-represented in previous trials and this study might provide important information to help guide future treatment options.
The study patients will be followed with standard of care procedures for 10 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50% of patients will be treated with standard TAVR procedure and followed up for 10 years
Procedure: transcatheter aortic valve replacement (TAVR)
50% of patients will be treated with standard SAVR procedure and followed up for 10 years
Procedure: surgical aortic valve replacement (SAVR)
percutaneous transcatheter aortic valve replacement
surgical aortic valve replacement
1 year hierarchical composite outcome of death, disabling stroke, non-disabling stroke, valve reintervention, rehospitalization, unfavorable KCCQ (VARC 3)
The primary endpoint will be analyzed by the Win ratio method14. That is, every patient in the TAVR group will be compared with every patient in the SAVR group to determine which pair has won. A win higher up in the hierarchy takes priority, so KCCQ gets used only for those pairs that were tied on the first 5 event components. Then KCCQ win is declared if the time-averaged change in KCCQ differs by 5 points or more. The win ratio= total wins on TAVR divided by total wins on SAVR, for which a 95% CI and p value is calculated.
Time frame: 1 year
Technical success at time of exit from OR/cath lab
defined as meeting of the following: * Alive * Successful access, delivery and retrieval of the device delivery system * Deployment and correct positioning (including repositioning /recapture if needed) of the single intended valve * No additional unplanned or emergency surgery or re-intervention prior to leaving OR/Cath lab related to the device or access procedure (includes need for return to bypass post initial wean
Time frame: exit from procedure (OR or cath lab)
Device success
Defined as meeting all of the following: * Alive and stroke-free * Original intended device in place * No additional surgical or interventional procedures related to access or the device since completion of the original procedure (i.e., exit from the cath lab/OR) * Intended performance of the device: 1. Structural performance: No migration, embolization, detachment, fracture, or thrombosis 2. Hemodynamic performance: Mean gradient \< 20mmHg, AVA \>1cm2, jet velocity \< 3.0 m/s 3. Absence of the following para-device complications (PVL \> mild, erosion, hemolysis, or endocarditis)
Time frame: 30 days
Procedural success
Defined as meeting all of the following: 1. Life-threatening bleed (BARC 3b or greater) 2. Major vascular or cardiac structural complications requiring unplanned reintervention or surgery 3. Stage 2 or 3 AKI (includes new dialysis) 4. MI or need for PCI/CABG 5. Severe heart failure or hypotension requiring IV inotrope \>12 hours, ultrafiltration or mechanical circulatory support 6. Prolonged intubation \> 48 hours 7. Need for a permanent pacemaker implant or continuous, new onset atrial fibrillation
Time frame: 30 Days
Patient success
Defined as meeting all of the following: * Device success * No re-hospitalizations or re-interventions for the underlying condition (e.g., Aortic stenosis and Heart Failure) * Return to prior living arrangement (or equivalent) * Improvement in symptoms defined as increase in NYHA Class \> 1 compared to Baseline * Improvement in functional status defined as 6MWT \> 25 m compared to Baseline * Improvement in quality-of-life defined as KCCQ score \> 10 compared to Baseline
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 36 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.